| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Protagonist Therapeutics Inc (STU: PGF)
PGF Technical Analysis
5
| As on 22nd Sep 2021 PGF SHARE Price closed @ 19.13 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 25.16 & Strong Sell for SHORT-TERM with Stoploss of 17.51 we also expect STOCK to react on Following IMPORTANT LEVELS. |
PGFSHARE Price
| Open | 19.05 | Change | Price | % |
| High | 19.15 | 1 Day | -13.71 | -90.20 |
| Low | 19.02 | 1 Week | -11.61 | -88.63 |
| Close | 19.13 | 1 Month | -39.11 | -96.33 |
| Volume | 240400 | 1 Year | -15.71 | -91.34 |
| 52 Week High 42.80 | 52 Week Low 1.49 | ||||
STU Germany Most Active Stocks
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| TINC | 0.01 | -1.50% |
| PGF | 19.13 | -90.20% |
| PGF | 19.13 | -90.20% |
| DMJ | 0.17 | 6.25% |
| DMJ | 0.17 | 6.25% |
STU Germany Top Gainers Stocks
STU Germany Top Losers Stocks
| PGF Daily Charts |
PGF Intraday Charts |
Whats New @ Bazaartrend |
PGF Free Analysis |
|
|
PGF Important Levels Intraday
| SUPPORT | 1.62 |
| SUPPORT | 1.58 |
| SUPPORT | 1.55 |
| SUPPORT | 1.53 |
| SUPPORT | 1.45 |
| SUPPORT | 1.43 |
| SUPPORT | 1.40 |
| SUPPORT | 1.36 |
PGF Forecast April 2024
| 4th UP Forecast | 9.97 |
| 3rd UP Forecast | 7.25 |
| 2nd UP Forecast | 5.57 |
| 1st UP Forecast | 3.89 |
| 1st DOWN Forecast | -0.91 |
| 2nd DOWN Forecast | -2.59 |
| 3rd DOWN Forecast | -4.27 |
| 4th DOWN Forecast | -6.99 |
PGF Weekly Forecast
| 4th UP Forecast | 10.74 |
| 3rd UP Forecast | 7.77 |
| 2nd UP Forecast | 5.94 |
| 1st UP Forecast | 4.11 |
| 1st DOWN Forecast | -1.13 |
| 2nd DOWN Forecast | -2.96 |
| 3rd DOWN Forecast | -4.79 |
| 4th DOWN Forecast | -7.76 |
PGF Forecast2024
| 4th UP Forecast | 81.13 |
| 3rd UP Forecast | 55.59 |
| 2nd UP Forecast | 39.8 |
| 1st UP Forecast | 24.01 |
| 1st DOWN Forecast | -21.03 |
| 2nd DOWN Forecast | -36.82 |
| 3rd DOWN Forecast | -52.61 |
| 4th DOWN Forecast | -78.15 |
Protagonist Therapeutics Inc ( STU Germany Symbol : PGF )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
PGF Business Profile
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service